Frequently Asked Questions

You've got questions. We've got answers.

FAQ

Expand allCollapse all
 

A registry is a place to store detailed medical information about people living with lung cancer.

Decision-makers in research, industry, policy, and healthcare settings are actively seeking robust sources of patient data to inform their work. The GO2 Foundation for Lung Cancer founded the registry as a global tool ideally positioned to capitalize on this growing interest by building a high-impact source of patient information. Registries give patients a direct means to participate in the care continuum, providing their input and insights to help focus priorities and improve outcomes for patients.

People living with lung cancer and their caregivers can participate in the registry. Caregivers of patients who are unable to participate due to age or health status, including those who are deceased, may also create an account and provide the patient’s data.

Children under the age of 18 cannot participate in the registry. Children who are younger than 18 years of age, or adults who cannot make their own medical decisions, must have their legal guardian, parent, or custodian register on their behalf. When children who are registered turn 18 (and if they are able), they will be asked if they want to continue participating. A parent, spouse, or an adult child of a patient who has died of lung cancer may also create an account.

It takes whole communities to help people living with medical conditions lead healthier and happier lives. The more information we collect about lung cancer, the closer we can get to finding treatments that work.

Collecting health information from as many people as possible helps researchers:

  • Speed up research by collecting information that scientists can use to develop better treatments and work towards a cure.
  • Study why individuals have different symptoms.
  • Learn about how certain treatments work and don’t work.
  • Help medical professionals improve how they treat affected individuals.
  • Keep patients informed about their eligibility for research studies or clinical trials.
  • Let those living with lung cancer (or their families) know when they may be eligible for research studies or clinical trials.